DLL3 Expression in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinomas
Abstract
Delta-like ligand 3 (DLL3) has been identified as a therapeutic target in high-grade neuroendocrine carcinomas, particularly small cell lung carcinoma. Data on DLL3 expression in medullary thyroid carcinoma (MTC) are limited; moreover, the relationship between DLL3 expression and MTC genotype has not been explored. We evaluated DLL3 expression (based on staining intensity and percentage of positive cells) in a genotyped cohort of sporadic MTC. In our cohort of 39 cases, 27 (69%) tumors were positive for DLL3, including 1 (4%) with low DLL3 expression, 10 (26%) with moderate expression, and 16 (41%) with high expression. DLL3 expression was significantly associated with grade ( P =0.036), presence of a RET mutation ( P =0.014), presence of lymph node metastases at diagnosis ( P
Fields of Study & Subjects
Neuroendocrine Tumor Research Advances
Lung Cancer Research Studies
Thyroid Cancer Diagnosis and Treatment
Publication details
- Journal / source
- The American Journal of Surgical Pathology
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 50
- Issue
- 9
- Pages
- 1076–1085
- Publication date
- 8 June 2026
- Language
- EN